Rates of major bleeding and intracranial hemorrhage are similar for apixaban and dabigatran versus aspirin, while rates are ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

The mean time to achieve therapeutic anticoagulation was significantly less in the anti-Xa HA group compared with the aPTT group (p < 0.0001). Furthermore, a significantly greater percentage of ...

Much of the research in optimizing anticoagulant therapy for acute VTE has been carried out in patients without malignancies. Given the aggressive natural history of VTE in cancer patients ...

The number of patients under anticoagulation therapy is on the rise, and thereby, the demand for anticoagulants also increases. In 2022, 702,880 people died from heart disease, and such deaths ...

Finnish biopharmaceutical company Aplagon has secured a financing of €7m ($7.24m) to advance its heparin proteoglycan mimetic ...

Financing led by new Investors Fåhraeus Startup and Growth and EIC FundHELSINKI, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Aplagon, a ...

Venus Remedies has received marketing authorization from Indonesia for its Enoxaparin, an anticoagulant, in pre-filled syringes. The approval reinforces the company's presence in Southeast Asia and ...

LOS ANGELES -- In the PRESTIGE-AF trial, survivors of intracerebral hemorrhage (ICH) had good protection against future ischemic events using direct oral anticoagulants (DOACs) -- though, as feared, ...

Age and hypertension are associated with increased risks for cranial ischemic complications in GCA, while anticoagulant therapy may offer protective benefits.

A single-center study suggests the surgery is safe and effective even when tumors are large or located in high-risk areas.

The benefit of direct oral anticoagulants on stroke risk in patients with prior intracerebral hemorrhage and atrial ...